Vir Biotechnology (NASDAQ:VIR – Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.93) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.51. Vir Biotechnology had a negative net margin of 677.69% and a negative return on equity of 32.58%. The firm had revenue of $56.38 million during the quarter, compared to analysts’ expectations of $11.71 million. During the same quarter in the prior year, the company earned ($1.06) EPS. The company’s revenue was down 10.5% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Vir Biotechnology Stock Down 1.9 %
Shares of VIR opened at $10.50 on Tuesday. The company has a 50 day moving average price of $9.90 and a 200-day moving average price of $9.82. Vir Biotechnology has a fifty-two week low of $7.61 and a fifty-two week high of $14.27.
Analysts Set New Price Targets
Read Our Latest Research Report on Vir Biotechnology
Insider Activity at Vir Biotechnology
In related news, Director Saira Ramasastry sold 4,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $10.95, for a total transaction of $43,800.00. Following the sale, the director now owns 14,619 shares in the company, valued at $160,078.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 15.60% of the stock is owned by company insiders.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.
Recommended Stories
- Five stocks we like better than Vir Biotechnology
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Should You Invest in Bonds? Here’s What to Know
- NYSE Stocks Give Investors a Variety of Quality Options
- Why This Manufacturer is Committing to a Massive Buyback Program
- There Are Different Types of Stock To Invest In
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.